Byotrol PLC Board Appointment (8702X)

TIDMBYOT

RNS Number : 8702X

Byotrol PLC

25 November 2014

Byotrol plc

BOARD APPOINTMENT

Byotrol plc ("Byotrol" or "the company", the leading AIM listed anti-microbial hygiene company, today announces the appointment of Dr Trevor Francis to its board as Chief Technology Officer with immediate effect.

Dr Francis has been working as a consultant to the Company in various positions over the last six years, particularly in consumer product development and commercialisation. Prior to joining Byotrol, Dr Francis spent 29 years at Unilever where he became Vice President of the Global R&D Homecare division and Head of the European Fabric Conditioners & Global Fragrance divisions.

Dr Francis is also a board trustee of the Liverpool School of Tropical Medicine where he serves on the Audit and Remuneration Committees.

Commenting on the appointment, Nicholas Martel, Chairman of Byotrol, said:

"We are delighted to welcome Trevor to the Board. His proven experience of delivering innovative products to market will be invaluable as we seek to consolidate on the recent improvements made within the Company."

The following information in relation to the appointment of Dr Francis is disclosed pursuant to Schedule 2(g) of the AIM Rules for Companies:

Full Name: Dr Thomas Trevor Francis

Age: 64

 
 Current Directorships and Partnerships   Directorships and Partnerships 
                                           held in the last five years 
 Tecnoform Associates Limited             None 
 Liverpool School of Tropical 
  Medicine 
 
 
                   Shareholding in Company   Options held over Company Shares   % Shareholding in Company post option 
                                                                                exercise 
 Trevor Francis    739,846                   2,250,000                          1.33% 
                  ------------------------  ---------------------------------  ---------------------------------------

Dr Francis does not have a cash bonus scheme for the financial year ending 31 March 2015.

The options for Dr Francis have been granted in the Company's Enterprise Management Incentive Scheme.

There are no other matters which are required to be disclosed pursuant to Schedule 2(g) of the AIM Rules for Companies.

Enquiries:

 
 Byotrol plc                                    01925 742 000 
 David Traynor - Chief Executive 
  Dawn Williams - Group Marketing Controller 
 
 finnCap Ltd                                    020 7220 0500 
 Geoff Nash 
 Christopher Raggett

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a leading anti-microbial technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

Powerful, long-lasting and gentle, Byotrol's products can be used stand alone or as an ingredient within existing products, where Byotrol can significantly improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives for everyone.

For more information, please go to www.byotrol.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAPGGMCGUPCGRC

Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Giu 2024 a Lug 2024